Discovery of antigen and toxin profiles in Clostridioides difficile disease

Discovery of antigen and toxin profiles in Clostridioides difficile disease - PaPrep_C.diff.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033279

Enrollment

130

Registered

2023-12-22

Start date

2023-12-12

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A04.7

Interventions

Group 1: People diagnosed with C.diff

A stool sample is collected on day 0 before administration of the antibiotics and then 24-48 hours later and optionally 10-14 days later. Group 2: People suffering from unspecific diaarhea, e.g. after

A stool sample is given only at one timepoint

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: signed written consent before undertaking any study specific activity available for the first two sample time points ( in the C.diff. group); 3rd timepoint is optional aged between 18-99 years

Exclusion criteria

Exclusion criteria: unable to provide consent underlying psychological disease Hepatitis A diagnosis

Design outcomes

Primary

Measure	Time frame
Presence of antigens and toxins before and after treatment against C.diff and comparison with healthy/diseased control groups to identify any cross-reactivity.	—

Secondary

Measure	Time frame
RNA and DNA signatures of pathogens in stool of C.diff. and control groups	—

Countries

Germany

Contacts

Public ContactAndreas Wieser

Abteilung für Infektions- und Tropenmedizin, LMU Klinikum München

Wieser@mvp.lmu.de+49 (0)89 2180-78296

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026